Odanacatib increases mineralized callus during fracture healing in a rabbit ulnar osteotomy model

Journal of Orthopaedic Research

Volumn 34, Issue 1, 2016, Pages 72-80

  Pennypacker, Brenda L ^a   Gilberto, David ^a   Gatto, Nicholas T ^a   Samadfam, Rana ^b   Smith, Susan Y ^b   Kimmel, Donald B ^a   Thi Duong, Le ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b CHARLES RIVER LABORATORIES   (United States)

Author keywords

callus formation; cathepsin K; fracture healing; osteoclast; rabbit

Indexed keywords

ALENDRONIC ACID; CATHEPSIN K; ODANACATIB; BIPHENYL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DENSITY; CALLUS; FEMALE; FRACTURE HEALING; NONHUMAN; OSTEOCLAST; OSTEOTOMY; PRIORITY JOURNAL; ULNA FRACTURE; ANIMAL; BONE MINERALIZATION; DRUG EFFECTS; RABBIT; RANDOMIZATION; ULNA;

ALENDRONATE; ANIMALS; BIPHENYL COMPOUNDS; BONY CALLUS; CALCIFICATION, PHYSIOLOGIC; FEMALE; FRACTURE HEALING; OSTEOTOMY; RABBITS; RANDOM ALLOCATION; ULNA;

EID: 84954075649     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.22982     Document Type: Article

References (27)

1. Gauthier JY, et al., 2008. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K 1. Bioorg Med Chem Lett 18: 923-928.
2. Duong LT,. 2012. Therapeutic inhibition of cathepsin K-reducing bone resorption while maintaining bone formation. Bonekey Rep 1: 67.
3. Gerstenfeld LC, et al., 2003. Fracture healing as a post-natal developmental process: molecular, spatial, and temporal aspects of its regulation. J Cell Biochem 88: 873-884.
4. Schindeler A, et al., 2008. Bone remodeling during fracture repair: the cellular picture. Semin Cell Dev Biol 19: 459-466.
5. Barnes GL, et al., 1999. Growth factor regulation of fracture repair. J Bone Miner Res 14: 1805-1815.
6. Gerstenfeld LC, et al., 2009. Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. J Bone Miner Res 24: 196-208.
7. Peter CP, et al., 1996. Effect of alendronate on fracture healing and bone remodeling in dogs. J Orthop Res 14: 74-79.
8. Bauss F, et al., 2004. New model for simulation of fracture repair in full-grown beagle dogs: model characterization and results from a long-term study with ibandronate. J Pharmacol Toxicol Methods 50: 25-34.
9. Little DG, Smith NC, Williams PR, et al. 2003. Zoledronic acid prevents osteopenia and increases bone strength in a rabbit model of distraction osteogenesis. J Bone Miner Res 18: 1300-1307.
10. Porras AG, Holland SD, Gertz BJ,. 1999. Pharmacokinetics of alendronate. Clin Pharmacokinet 36: 315-328.
11. Kostenuik PJ,. 2005. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 5: 618-625.
12. Gentile MA, Soung do Y, Horrell C, et al. Increased fracture callus mineralization and strength in cathepsin K knockout mice. Bone 66: 72-81.
13. Soung do Y, Gentile MA, Duong LT, et al. 2013. Effects of pharmacological inhibition of cathepsin K on fracture repair in mice. Bone 55: 248-255.
14. Stroup GB, Lark MW, Veber DF, et al. 2001. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate 1. J Bone Miner Res 16: 1739-1746.
15. Pennypacker BL, Oballa RM, Levesque S, et al. 2013. Cathepsin K inhibitors increase distal femoral bone mineral density in rapidly growing rabbits. BMC Musculoskelet Disord 14: 344.
16. Pennypacker BL, et al., 2011. Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits. J Bone Miner Res 18: 252-262.
17. Li RH, Bouxsein M, Blake CA, et al. 2003. RhBMP-2 injected in a calcium phosphate paste (alpha-BSM) accelerates healing in the rabbit ulnar osteotomy model. J Orthop Res 21: 997-1004.
18. Luppen CA, Blake CA, Ammirati KM, et al. 2002. Recombinant human bone morphogenetic protein-2 enhances osteotomy healing in glucocorticoid-treated rabbits. J Bone Miner Res 17: 301-310.
19. Leung P, Pickarski M, Zhuo Y, et al. 2011. The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking. Bone 49: 623-635.
20. Hak DJ, Fitzpatrick D, Bishop JA, et al. Delayed union and nonunions: epidemiology, clinical issues, and financial aspects. Injury 45: S3-S7.
21. Capone A, Orgiano F, Pianu F, et al., Orthopaedic surgeons' strategies in pharmacological treatment of fragility fractures. Clin Cases Miner Bone Metab 11: 105-109.
22. Little DG, Ramachandran M, Schindeler A,. 2007. The anabolic and catabolic responses in bone repair. J Bone Joint Surg Br 89: 425-433.
23. McDonald MM, Dulai S, Godfrey C, et al. 2008. Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling. Bone 43: 653-662.
24. Masarachia PJ, Pennypacker BL, Pickarski M, et al. 2012. Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys. J. Bone Miner Res 1: 509-523.
25. Zhuo Y, Gauthier JY, Black WC, et al. Inhibition of bone resorption by the cathepsin K inhibitor odanacatib is fully reversible. Bone 67: 269-280.
26. Eisman JA, Bone HG, Hosking DJ, et al. 2011. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect 1. J Bone Miner Res 26: 251.
27. Hughes DE, Wright KR, Uy HL, et al. 1995. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10: 1478-1487.